TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00947960

Intervention type: DRUG
Group type: OTHER
Intervention: Triheptanoin
Description: 1-2 grams triheptanoin (drug)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months followed by 1-2 grams vegetable oil (placebo)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months.

Intervention type: DRUG
Group type: OTHER
Intervention: Triheptanoin
Description: 1-2 grams triheptanoin (drug)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months followed by 1-2 grams vegetable oil (placebo)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months.
Study: NCT04035603

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Open Phase CBT that preceeds the randomization phase
Description: Four sessions of weekly individual cognitive-behavior therapy (CBT: a form of psychotherapy that treats problems by helping people modify thoughts, behaviors, and emotions; in this case, for the goal of smoking cessation). Session topics include educational (e.g., health risks of smoking, effectiveness of different treatment approaches), motivational enhancement (e.g., identifying personally relevant benefits of quitting, and costs of continuing to smoke), and cognitive-behavioral elements (e.g., identifying smoking triggers, developing coping strategies for these triggers, planning for high risk situations, relapse prevention).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Open Phase CBT that preceeds the randomization phase
Description: Four sessions of weekly individual cognitive-behavior therapy (CBT: a form of psychotherapy that treats problems by helping people modify thoughts, behaviors, and emotions; in this case, for the goal of smoking cessation). Session topics include educational (e.g., health risks of smoking, effectiveness of different treatment approaches), motivational enhancement (e.g., identifying personally relevant benefits of quitting, and costs of continuing to smoke), and cognitive-behavioral elements (e.g., identifying smoking triggers, developing coping strategies for these triggers, planning for high risk situations, relapse prevention).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open phase smoking cessation pharmacotherapy that proceeds the randomization phase
Description: Initiating 2 weeks prior to quit date and continuing for 8 weeks after quit date, choice of one of three pharmacological smoking cessation aids: Nicotine Replacement Therapy (nicotine patch), Varenicline, or Bupropion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Open phase smoking cessation pharmacotherapy that proceeds the randomization phase
Description: Initiating 2 weeks prior to quit date and continuing for 8 weeks after quit date, choice of one of three pharmacological smoking cessation aids: Nicotine Replacement Therapy (nicotine patch), Varenicline, or Bupropion.
Study: NCT04104633

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood samples
Description: 30 ml of blood collection
Study: NCT00947960

Intervention type: OTHER
Group type: OTHER
Intervention: Vegetable Oil
Description: 1-2 grams vegetable oil (placebo)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months followed by 1-2 g triheptanoin (drug)/kilogram body weight for 6 months.
Study: NCT01149629

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Droxidopa
Description: One capsule containing 300 mg droxidopa, given once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Droxidopa
Description: 3 capsules each containing 100 mg droxidopa, give 3 times at 4 hour intervals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Droxidopa
Description: 3 capsules each containing 100 mg droxidopa, given once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Droxidopa
Description: 3 capsules each containing 100 mg droxidopa, given once
Study: NCT03967730

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Sonodynamic therapy(SDT)
Description: Sonodynamic Therapy (SDT) Sinoporphyrin Sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml DVDMS solution intravenous injection(0.2mg/kg).The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site for 15 min of each lesion. Ultrasound parameters included intensity of 2.1W/cm2 for each lesion, resonance frequency: 1.0 MHz and duty factor: 30%.
Study: NCT01491880

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist-Assisted by Telephone
Description: Parents will receive educational workbooks and ongoing support over the phone from a child anxiety specialist to learn how to use cognitive behavioral therapy skills to manage their children's fears and worries.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Help
Description: Parents will receive educational workbooks to learn how to use cognitive behavioral therapy skills to manage their children's fears and worries independently. Parents will have the option to access support over the phone from a child anxiety specialist.
Study: NCT01636609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tosedostat
Description: Given PO
Study: NCT03280979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose methotrxate
Description: In the high dose MTX protocol, the patients will receive 100 mg/m2 intravenous (IV) MTX bolus followed by 200 mg/m2IV MTX infused over 12 hours followed by folinic acid
Study: NCT00584870

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Oral naproxen 500 mg twice daily for Weeks 1-12.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single IV infusion of placebo on Day 1 and placebo for naproxen twice daily for Weeks 1-12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04383119 (RN624)
Description: Single IV infusion of 200 micrograms/kg RN624 on Day 1
Study: NCT01239355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor MK2206
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01636609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tosedostat
Description: Given PO
Study: NCT05343637

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)
Description: RT234 is a drug/device combination product composed of vardenafil hydrochloride as the drug constituent and will utilize RS01 DPI device.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)
Description: RT234 is a drug/device combination product composed of vardenafil hydrochloride as the drug constituent and will utilize RS01 DPI device.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)
Description: RT234 is a drug/device combination product composed of vardenafil hydrochloride as the drug constituent and will utilize RS01 DPI device.
Study: NCT01063556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donepezil HCl
Description: Subjects will receive donepezil HCL 3 mg without haemodialysis. After an interval of over 15 days, the subjects will receive donepezil 3 mg with haemodialysis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donepezil HCl
Description: Subjects will receive donepezil HCl 3 mg with haemodialysis. After an interval of over 15 days, the subjects will receive donepezil 3 mg without haemodialysis.
Study: NCT04395677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-106
Description: Stage 1: 400mg QD for 3 patients and 600mg QD for 3 patients~Stage 2: 600mg QD
Study: NCT03536884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will receive bimekizumab at pre-specified time-points.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will receive bimekizumab at pre-specified time-points.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimekizumab
Description: Subjects will receive bimekizumab at pre-specified time-points.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secukinumab
Description: Subjects will receive secukinumab at pre-specified time-points.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo at pre-specified time-points to maintain the blinding in the double-blind Treatment Period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo at pre-specified time-points to maintain the blinding in the double-blind Treatment Period.
Study: NCT02323880

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given PO
Study: NCT02548637

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture Therapy
Description: The standard textbook of Chinese Acupuncture and Moxibustion is the source for the name and location of the points for this study. A total of 38 points will be used, divided between two acupuncture sessions: 20 points or 37 locations in the supine position; 18 points or 36 locations in the prone position. Other than points governing vessel (GV) 20, conception vessel (CV) 6, CV 10, all points will be performed bilaterally.
Study: NCT02135380

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Autologous Stromal Vascular Fraction (SVF)
Description: Study arm A subjects will receive single dose of autologous adipose derived Stromal Vascular Fraction (SVF) intravenously.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Autologous Adipose Derived MSCs (ADMSCs)
Description: Study arm B subjects will receive total 3 doses of 2 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously each. All the three doses will be given at weekly intervals.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard Therapy
Study: NCT02127255

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual acupuncture implemented by acupuncturist 1
Description: Manual acupuncture once per day. Acupuncture treatment regimens (acupoints, needling methods, needle retention time) were decided by acupuncturist 1 according to the syndrome differentiation of patients. Acupuncturist 1 has to have more than 15 years of acupuncture clinical practice experience.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual acupuncture implemented by acupuncturist 2
Description: Manual acupuncture given by acupuncturist 2 once per day. Acupuncture treatment regimens (acupoints, needling methods, needle retention time) were decided by acupuncturist 1 according to the syndrome differentiation of patients. Acupuncturist 2 has to have less than 5 years of acupuncture clinical practice experience.
Study: NCT02363075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamfetamine sulphate
Description: 10mg/day per os for the first ten days, 20mg/day for the ten following days, 30mg/day until D90.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 10mg/day per os for the first ten days, 20mg/day for the ten following days, 30mg/day until D90.
Study: NCT04909684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: The approved doses of 400 mg every 6 weeks (Q6W) and 200 mg every 3 weeks (Q3W) will be decreased to a 300 mg Q6W dose. The approved dose of 150 mg Q3W will be decreased to a 100 mg Q3W dose.
Study: NCT00631137

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: testosterone gel applied to skin
Description: Application of testosterone gel

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: whey powder protein
Study: NCT03668509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1459
Description: oral adminstration, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1459
Description: oral adminstration, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1459
Description: oral adminstration, single dose
Study: NCT02537288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fedovapagon
Study: NCT03137615

Intervention type: PROCEDURE
Intervention: Pituitary surgery
Description: Trans-sphenoidal resection of a pituitary gland lesion.

Intervention type: DRUG
Intervention: local anaesthetic injection
Description: The surgeon infiltrates the nasal septum with local anaesthesia as per usual practice. This consists of Moffet's solution and lidocaine with adrenaline (1:200,000).
Study: NCT03891147

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Study: NCT04479904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: po
Study: NCT00996203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg iv every 4 weeks for 24 weeks
Study: NCT01417390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Gemcitabine and cisplatin
Description: Patients receive Gemcitabine (1000mg/m2 on day 1,8) and cisplatin (20mg/m2 on day 1-4) every three weeks for two cycles before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (40mg/m2) every week for six cycles during radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Patients receive radical radiotherapy and cisplatin (40mg/m2) every week for six cycles during radiotherapy
Study: NCT00996203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMARDs (disease-modifying antirheumatic drugs)
Description: stable doses at investigator's prescription
Study: NCT01740180

Intervention type: OTHER
Intervention: Data entry
Description: This cohort describes the basic information about the patients (age, sex, weight, height, background) as well as acts required, treatment and results of imaging studies.~These data are extracted from patient records by each participating center and collected in an e-CRF.
Study: NCT02401334

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cook® Antimicrobial Hernia Repair Device
Description: Device containing an antimicrobial to reinforce soft tissue during ventral or incisional hernia repair in clean-contaminated, contaminated, and dirty-infected
Study: NCT04004091

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Spermine
Description: Spermine is a polyamine. It is an organic molecule that is involved in cellular metabolism and development.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Spermine
Description: Spermine is a polyamine. It is an organic molecule that is involved in cellular metabolism and development.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Spermine
Description: Spermine is a polyamine. It is an organic molecule that is involved in cellular metabolism and development.
Study: NCT02733120

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stable isotope infusion
Description: stable isotopes such as 15N2, TRP, 2H3-Leucine, L-\[2H3\]-3-Methylhistidine, 2H2-Glycine, 2-D-hydroxyproline, 1-13C-ketoisocaproic acid (KIC), L-\[Guanido-15N2\]-Arginine, L-\[ureido-13C-2H2\]-Citrulline), L-Glutamine-amide-15N, 1,2-13C2-L-Glutamic acid, 1,2-13C2Taurine, and 13C-Urea is given IV simultaneously
Study: NCT03787589

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Prescription
Description: Participants in the intervention group will be given an exercise prescription to increase their baseline steps by 1200 and 2000 steps per day at least 3 days a week over the first 3 months. If tolerated and accepted, the participants will increase their step counts by an additional 600 to 1000 steps per day at least 3 days a week for the next 3 months.This will be followed by a 6-month maintenance phase. The research coordinator will instruct the participants on the proper use of the Nordic walking poles which can be used to help participants achieve their prescribed number of steps.~All participants will be encouraged to wear the pedometer throughout the trial in order to follow the step-count prescription and monitor adherence.
Study: NCT00848120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8mg/kg iv every 4 weeks for 24 weeks
Study: NCT02344225

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine citrate
Description: Caffeine citrate IV (20 mg/kg loading dose, 5 mg/kg/day maintenance dose)
Study: NCT02537288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fedovapagon

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for fedovapagon)
Study: NCT02344225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen (10 mg/kg loading dose followed by low dose ibuprofen 2.5 mg/kg/day) for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Ketorolac (Acuvail) eye drops (one drop two times a day) for 14 days
Study: NCT00772447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: 4mg/kg IV ; Q 24 hr (once every 24 hours)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin - 1g per 12 hrs, for 7-14 days~Or switch to~Vancomycin Followed by Semi-synthetic Penicillin-Cloxacillin:~- 1 g every 6 hours or 2 g every 8 hours
Study: NCT01951677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBsAg
Description: Standard hepatitis B vaccine antigen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBsAg
Description: Standard hepatitis B vaccine antigen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBsAg
Description: Standard hepatitis B vaccine antigen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HBsAg
Description: Standard hepatitis B vaccine antigen
Study: NCT00183794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel and Gemcitabine
Description: Docetaxel 75 mg/m2 IV over 15-30 minutes on day 1 followed by Gemcitabine 800 mg/m2 IV over 30 minutes on Days 1 and 8 of each 3 weeks (21 days) cycle.
Study: NCT02183415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 BS, low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 BS, medium dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 BS, high dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02592226

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anesthesia: alveolar recruitment maneuver

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anesthesia: standardized
Study: NCT01851733

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI-guided Laser Heat Ablation (MLA)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI-guided Laser Heat Ablation (MLA)
Study: NCT01951677

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PreS HBsAg
Description: preS hepatitis B surface antigen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PreS HBsAg
Description: preS hepatitis B surface antigen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PreS HBsAg
Description: preS hepatitis B surface antigen

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PreS HBsAg
Description: preS hepatitis B surface antigen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PreS HBsAg
Description: preS hepatitis B surface antigen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PreS HBsAg
Description: preS hepatitis B surface antigen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PreS HBsAg
Description: preS hepatitis B surface antigen

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PreS HBsAg
Description: preS hepatitis B surface antigen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Advax-1(TM)
Description: Adjuvant formulated with vaccine antigen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Advax-1(TM)
Description: Adjuvant formulated with vaccine antigen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Advax-1(TM)
Description: Adjuvant formulated with vaccine antigen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Advax-2(TM)
Description: Adjuvant formulated with vaccine antigen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Advax-2(TM)
Description: Adjuvant formulated with vaccine antigen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Advax-2(TM)
Description: Adjuvant formulated with vaccine antigen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Advax-3(TM)
Description: Adjuvant formulated with vaccine antigen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Advax-3(TM)
Description: Adjuvant formulated with vaccine antigen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Advax-3(TM)
Description: Adjuvant formulated with vaccine antigen

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Alum
Description: Adjuvant formulated with vaccine antigen

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Alum
Description: Adjuvant formulated with vaccine antigen

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Alum
Description: Adjuvant formulated with vaccine antigen
Study: NCT04502303

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-FDG and 68Ga-FAPI PET/CT
Description: Participants will undergo 18F-FDG (0.12-0.15mCi/kg) and 68Ga-FAPI (3-6mCi) PET/CT on two consecutive days. At least 6 hours of fast is required for 18F-FDG PET scan, while no dietary control is necessary for 68Ga-FAPI PET scan. If the patients are on metformin, discontinuation of 48 hours is required before 18F-FDG injection to minimize the bowel uptake. If the patient is planned for surgical resection of one or more stricture (s), the scans have to be completed within a maximum period of 30 days before the surgery.